All In Biotech

Drug Trial Radar · NCT06842537

Study of SYH2062 Injection in Healthy Chinese Volunteers

A Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SYH2062 Injection in Healthy Chinese Volunteers

Last checked: Nov 20, 2026Latest source record: Apr 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

46

Planned (sponsor's estimate)

Start

Mar 1, 2025

Primary completion

Dec 31, 2025

Study completion Dec 31, 2025

Sponsor

Sponsor type
Industry
First posted
Feb 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, efficacy, pharmacodynamics and pharmacokinetics of SYH2062 injection in healthy Chinese volunteers

Conditions

  • Healthy Chinese Volunteers

Interventions

  • SYH2062 injectionDrug

    SYH2062 for sc injection

  • SYH2062-Matching placeboDrug

    Normal saline matching volume of SYH2062 doses will be administered

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Adverse Events (AEs)Time frame: up to approximately 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Chinese Academy of Medical Science and Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.